LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Stability of Cardiac Biomarkers Tested in Different Samples

By LabMedica International staff writers
Posted on 09 Jan 2018
Image: The ARCHITECT i2000SR immunoassay analyzer (Photo courtesy of Abbott Diagnostics).
Image: The ARCHITECT i2000SR immunoassay analyzer (Photo courtesy of Abbott Diagnostics).
Blood-based biomarkers, such as cardiac troponin (cTn) and galectin-3, are widely used in clinical trials and/or in clinical routines as an aid for the diagnosis and risk stratification of patients with heart disease.

When blood samples are used for biomarker measurements in clinical routine analyses, efforts should be made to process these samples immediately after blood collection to provide immediate results for timely diagnosis and therapy and to avoid any pre-analytical errors.

Doctors at Konventhospital Barmherzige Brueder Linz, (Linz, Austria) tested the hypothesis that the analytes hs-cTnI, hs-cTnT and galectin-3 are stable in vitro at a storage temperature of −80 °C for at least one year, and they used blood samples from clinical routine analyses. The analyte concentrations of 30 patients were measured in heparin-treated plasma, EDTA-treated plasma and serum samples after the following storage conditions: 1) samples used immediately after blood collection for baseline measurements; 2) samples stored for six months at −80 °C after one freeze-thaw cycle; 3) samples stored for one year at −80 °C after two freeze-thaw cycles; and 4) samples stored for one year at −80 °C after one freeze-thaw cycle.

Circulating concentrations of high-sensitivity cardiac troponin I (hs-cTnI) were measured with the STAT High Sensitive Troponin-I assay on the Abbott ARCHITECT i2000SR analyzer. The team measured hs-cTnT concentrations with the Troponin T hs assay on the Roche cobas e 411. The scientists also measured galectin-3 with the Abbott Diagnostics routine Galectin-3 assay on an ARCHITECT i2000SR analyzer.

The investigators reported that baseline hs-cTnI, hs-cTnT and galectin-3 concentrations ranged from 2.3 to 5,436 ng/L, from 5.3 to 850 ng/L, and from 8.3 to 79.3 ng/mL, respectively. After applying the default criterion for analyte stability, the three analytes were stable for at least one year even after two freeze-thaw cycles for each sample type. They observed the following variation in analyte concentrations after storage relative to the baseline values: the interquartile range (IQR) of cardiac troponin results extended from approx. 80% to 115%, and the IQR of galectin-3 results extended from approx. 90% to 110%.

The authors concluded that hs-cTnI, hs-cTnT and galectin-3 were stable under the reported storage conditions irrespective of the sample type used. However, they observed a considerable variation in analyte concentrations after sample storage, which might affect the diagnostic/prognostic value of these analytes in individual patients using frozen blood samples. The study was published in the January 2018 issue of the journal Clinica Chimica Acta.

Related Links:
Konventhospital Barmherzige Brueder

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Automatic Hematology Analyzer
DH-800 Series

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more